TIDMIMM

RNS Number : 4375Z

Immupharma PLC

14 September 2022

14 September 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

Written Response received from the FDA

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that, further to the Company's notification of 7 July 2022, its US partner for Lupuzor(TM) (P140), Avion Pharmaceuticals ("Avion"), has received a written response from the Food and Drug Administration ("FDA") to the Type C meeting.

The FDA response was detailed and included significant guidance on next steps for the clinical programme. This included advice on the dosing regime. In addition, the FDA also provided further significant guidance on the study protocol that can be amended to improve the regulatory outcome.

The Company is currently reviewing the written response with Avion and will make a further notification in due course.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Ends

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chief Executive Officer         +44 (0) 207 206 2650 
 
   Lisa Baderoon, Head of Investor Relations      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                  +44 (0) 203 36 8 3550 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge, John Howes, Bob Pountney     +44 (0) 20 3650 3650 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBKQBKCBKKDCD

(END) Dow Jones Newswires

September 14, 2022 05:04 ET (09:04 GMT)

Immupharma (AQSE:IMM.GB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Immupharma Charts.
Immupharma (AQSE:IMM.GB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Immupharma Charts.